Alkem Laboratories Limited has informed the Exchange about USFDA inspection at the manufacturing facility of Enzene Biosciences Limited, a subsidiary of the Company in India
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories has informed the stock exchange that its subsidiary Enzene Biosciences Limited's manufacturing facility in India is undergoing a USFDA (United States Food and Drug Administration) inspection. No specific details about the outcome, observations, or duration of the inspection have been provided in this announcement. This is a routine disclosure under listing requirements for material events. Enzene Biosciences is a key subsidiary of Alkem and is involved in biologics and biosimilar manufacturing.
Neutral in the short term - investors should watch for the inspection outcome as USFDA observations or warning letters could impact future US export approvals and revenues, while a clean inspection would be a positive signal.